It is important to highlight that USP39 serves as a tumor-promoting factor in the majority of malignant cancers, and the combination of cisplatin and USP39 inhibitors may effectively improve the sensitivity of patients to the drug and enhance the therapeutic effect. This evidence concerns the gene USP39 and neoplasm.